NCT01624246 - Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Augmented Renal Clearance (ARC)Systemic Inflammatory Response Syndrome (SIRS)

Interventions

DRUG

Ceftaroline fosamil/Avibactam (CXL)

IV infusion of CXL (combination of ceftaroline fosamil \[600 mg\] plus avibactam \[600 mg\]) infused over 60 (± 5) minutes.

Trial Locations (21)

4029

Investigational Site, Herston

4215

Investigational Site, Southport

20010

Investigational Site, Washington D.C.

27157

Investigational Site, Winston-Salem

32610

Investigational Site, Gainesville

33136

Investigational Site, Miami

43210

Investigational Site, Columbus

44106

Investigational Site, Cleveland

45409

Investigational Site, Dayton

55805

Investigational Site, Duluth

60153

Investigational Site, Maywood

60612

Investigational Site, Chicago

61606

Investigational Site, Peoria

68131

Investigational Site, Omaha

77401

Investigational Site, Houston

90033

Investigational Site, Los Angeles

92123

Investigational Site, San Diego

93711

Investigational Site, Fresno

94605

Investigational Site, Stanford

06102

Investigational Site, Hartford

07753

Investigational Site, Neptune City